ELVIRA DEOLINDA RODRIGUES PEREIRA VELLOSO

(Fonte: Lattes)
Índice h a partir de 2011
12
Lattes
ResearcherID
ORCID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Clínica Médica, Faculdade de Medicina - Docente
LIM/31 - Laboratório de Genética e Hematologia Molecular, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Autor: VELLOSO, Elvira D. R. P. ×

Resultados de Busca

Agora exibindo 1 - 10 de 23
  • article 6 Citação(ões) na Scopus
    Flow cytometry ""Ogata score"" for the diagnosis of myelodysplastic syndromes in a real-life setting. A Latin American experience
    (2019) MONTAUBAN, Sofia Grille; HERNANDEZ-PEREZ, Carlos R.; VELLOSO, Elvira D. R. P.; NOVOA, Viviana; LORAND-METZE, Irene; GONZALEZ, Jaqueline; SOLARI, Liliana; CISMONDI, Valeria; SERRANO, Juan Carlos; BURGNINI, Andreina; RABELO-CARRASCO, Laura J.; BACAL, Nydia; TRIAS, Natalia; GUEVARA, Romina; VIDO, Joyce Rico; CRISP, Renee; ENRICO, Alicia; BOADA, Matilde; CUNHA, Fernanda G. Pereira; FANESSI, Viviana; VENEGAS, Maria Belen; ISSOURIBEHERE, Diego; NOVOA, Andrea; LENS, Daniela
    Introduction Flow cytometry (FC) is a helpful tool for the diagnosis of myelodysplastic syndrome (MDS). Different FC score systems have been developed. The ""Ogata score"" is a simple diagnostic score that has been validated having a sensitivity of 69% and a specificity of 92% in low-risk MDS. We aimed to study the feasibility and the utility of the ""Ogata score"" for the diagnosis of MDS among Latin America (LA) Laboratories. Methods This is a case and control study conducted in LA institutions members of Grupo Latinoamericano de Mielodisplasia (GLAM). A total of 146 MDS patients and 57 control patients were included. ""Ogata score"" was calculated. Results The sensitivity of ""Ogata score"" was 75.6% (95% CI, 66.8-81.3), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 95.6% (95% CI, 88.5-98.3), and NPV was 65.4% (95% CI, 49.1-71.9). In low/intermediate-1 IPSS patients group, the sensitivity was 70.1% (95% CI, 60.2-78.2), specificity was 91.2% (CI-95%, 79.7-96.7), PPV was 94.2% (95% CI, 86.4-97.8), and NPV was 62.1% (95% CI, 53.0-78.7). In the group of patients ""without MDS specific markers"" (patients without ring sideroblasts, blast excess, or chromosomal abnormalities), the sensitivity was 66.7% (CI-95%, 55.8-76.0), specificity was 91.2% (95% CI, 79.7-96.7), PPV was 92.3% (95% CI, 82.2-97.1), and NPV was 63.5% (95% CI, 51.9-73.5). Conclusions The diagnostic power found in this study was similar to the reported by Della-Porta et al. Also in LA, the analysis was made in modern equipment with acquisition of at least 100 000 events which permits a good reproducibility of the results.
  • conferenceObject
    Venetoclax and Azacytidine Therapy in High-Risk Myelodysplastic Syndromes: A Retrospective Evaluation of a RealWorld Experience. Latin-American MDS Group - Glam
    (2022) IASTREBNER, Marcelo; CRISP, Renee Leonor; OVILLA, Roberto; LEON, Andres Gomez-De; PUENTE, Adriana Karola; DUARTE, Fernando Barroso; VELLOSO, Elvira D. R. P.; GUSMAO, Breno; VARELA, Ana; BOADA, Matilde; GRILLE, Sofia
  • conferenceObject
    Myelodysplastic Syndromes in Latin-America - Results from a Novel International Registry: Re-Glam
    (2022) GRILLE, Sofia; VELLOSO, Elvira D. R. P.; BOADA, Matilde; CHAVEZ, Elia Apodaca; LEON, Andres Gomez-De; RODRIGUEZ-ZUNIGA, Anna Cecilia; MORENO, Emmanuel Martinez; PEREZ-JACOBO, Fernando; ALFONSO, Graciela; SERRANO, Juan Carlos; TEJEIRA, Natalia; DIAZ, Lilian; OLIVARES, Valentina; KORNBLIHTT, Laura; SCHUSTERSCHITZ, Sergio; IASTREBNER, Marcelo
  • article 5 Citação(ões) na Scopus
    Toxicity Profile of PEG-Asparaginase in Adult Patients With Acute Lymphoblastic Leukemia in Brazil: A Multicenter Cross-Sectional Study
    (2020) SILVA, Wellington F. da; MASSAUT, Ires H. B.; BENDLIN, Rodrigo M.; ROSA, Lidiane I.; VELLOSO, Elvira D. R. P.; REGO, Eduardo M.; ROCHA, Vanderson
    Pegylated asparaginase was recently approved for use in Brazil. We reviewed its toxicity in adults with acute lymphoblastic leukemia. Fifty-seven patients were included, with remarkable thromboembolic (17%) and hepatic (77%) event rates. No fatal event was registered. Our incidence is similar to those reported in other trials. These effects should not preclude further use because most events are manageable. Background: Currently, pediatric-inspired regimens are commonly applied to adults with acute lymphoblastic leukemia (ALL) after the recent recognition that these protocols improve survival. While asparaginase in whatever available formulation is a key component of modern treatment of ALL, many adult oncologists and hematologists struggle to deal with its particular toxicities in clinical practice. We reviewed toxicity outcomes of pegylated asparaginase (PEG-ASP) in adults with ALL treated in 3 reference centers in Brazil. Patients and Methods: This was a cross-sectional retrospective chart-review study encompassing patients aged 15 years and older diagnosed with ALL or ambiguous-lineage leukemia who received at least one dose of PEG-ASP, regardless of the adopted regimen. Results: A total of 57 patients were included (age range, 15-57 years). Most patients (70%) received 2000 IU/m(2) as the initial dose, by intravenous route (72%). The incidence of thromboembolic events was 17.5%, and the main site was cerebral venous sinus (4/10). Thrombosis was more frequent in patients receiving second-line treatment. In obese patients, grade 3 hepatotoxicity and hyperbilirubinemia were more common. Clinical pancreatitis (grade 3 or higher) was found in 2 of 57 cases. PEG-ASP had to be discontinued in 19.3% of exposed patients (11/57). Conclusion: By reviewing the medical charts of adult patients with ALL from 3 reference centers, we found that our incidence of thrombotic and hepatic adverse events is similar to those reported in other trials involving PEG-ASP. Usually these effects should not preclude further use of the drug because most events are manageable in routine clinical practice.
  • article 1 Citação(ões) na Scopus
    Assessment of Bone Microarchitecture in Patients with Systemic Mastocytosis and its Association with Clinical and Biochemical Parameters of the Disease
    (2023) FRANCO, Andre S.; MURAI, Igor H.; TAKAYAMA, Liliam; CAPARBO, Valeria F.; MARCHI, Luan L.; VELLOSO, Elvira D. R. P.; PEREIRA, Rosa M. R.
    Patients with systemic mastocytosis (SM) are at high risk of bone deterioration. However, the evaluation of bone microarchitecture in this disease remains unclear. We aimed to assess bone microarchitecture in patients with SM. This was a cross-sectional study of 21 adult patients with SM conducted in a quaternary referral hospital in Sao Paulo, Brazil. A healthy, age-, weight-, and sex-matched cohort of 63 participants was used to provide reference values for bone microarchitecture, assessed by high resolution peripheral quantitative computed tomography (HR-pQCT). Total volumetric bone mineral density (vBMD), cortical vBMD, and cortical thickness at the radius were significantly lower in the control group compared with the SM group (all P < 0.001). Patients with aggressive SM had significantly lower trabecular number (Tb.N) (P = 0.035) and estimated failure load (F.load) (P = 0.032) at the tibia compared with those with indolent SM. Handgrip strength was significantly higher in patients who had more Tb.N at the radius (rho, 0.46; P = 0.036) and tibia (rho, 0.49; P = 0.002), and lower who had more trabecular separation at the radius (rho, -0.46; P = 0.035) and tibia (rho, -0.52; P = 0.016). Strong and positive associations between F.load (rho, 0.75; P < 0.001) and stiffness (rho, 0.70; P < 0.001) at the radius, and between F.load at the tibia (rho, 0.45; P = 0.038) were observed with handgrip strength. In this cross-sectional study, aggressive SM was more susceptible to bone deterioration compared with indolent SM. In addition, the findings demonstrated that handgrip strength was associated with bone microarchitecture and bone strength.
  • article 1 Citação(ões) na Scopus
    Cytogenetic studies for cMYC, BCL2 and BCL6 genes in neoplasm: comparison of karyotype, FISH in paraffin-embedded tissue and FISH in methanol-acetic acid-fixed cells suspensions
    (2021) GARCIA, Caroline Henriques; SILVA, Roberta Maria da; SAFRANAUSKAS, Oliveira; BEZERRA, Alanna Mara P. S.; VELLOSO, Elvira D. R. P.
  • article 9 Citação(ões) na Scopus
    Differential diagnosis of bone marrow failure syndromes guided by machine learning
    (2023) GUTIERREZ-RODRIGUES, Fernanda; MUNGER, Eric; MA, Xiaoyang; GROARKE, Emma M.; TANG, Youbao; PATEL, Bhavisha A.; CATTO, Luiz Fernando B.; CLE, Diego V.; NIEWISCH, Marena R.; ALVES-PAIVA, Raquel M.; DONAIRES, Flavia S.; PINTO, Andre Luiz; BORGES, Gustavo; SANTANA, Barbara A.; MCREYNOLDS, Lisa J.; GIRI, Neelam; ALTINTAS, Burak; FAN, Xing; SHALHOUB, Ruba; SIWY, Christopher M.; DIAMOND, Carrie; RAFFO, Diego Quinones; CRAFT, Kathleen; KAJIGAYA, Sachiko; SUMMERS, Ronald M.; LIU, Paul; CUNNINGHAM, Lea; HICKSTEIN, Dennis D.; DUNBAR, Cynthia E.; PASQUINI, Ricardo; OLIVEIRA, Michel Michels De; VELLOSO, Elvira D. R. P.; ALTER, Blanche P.; SAVAGE, Sharon A.; BONFIM, Carmem; WU, Colin O.; CALADO, Rodrigo T.; YOUNG, Neal S.
    The choice to postpone treatment while awaiting genetic testing can result in significant delay in definitive therapies in patients with severe pancytopenia. Conversely, the misdiagnosis of inherited bone marrow failure (BMF) can expose patients to ineffectual and expensive therapies, toxic transplant conditioning regimens, and inappropriate use of an affected family member as a stem cell donor. To predict the likelihood of patients having acquired or inherited BMF, we developed a 2-step data-driven machine-learning model using 25 clinical and laboratory variables typically recorded at the initial clinical encounter. For model development, patients were labeled as having acquired or inherited BMF depending on their genomic data. Data sets were unbiasedly clustered, and an ensemble model was trained with cases from the largest cluster of a training cohort (n = 359) and validated with an independent cohort (n = 127). Cluster A, the largest group, was mostly immune or inherited aplastic anemia, whereas cluster B comprised underrepresented BMF phenotypes and was not included in the next step of data modeling because of a small sample size. The ensemble cluster A-specific model was accurate (89%) to predict BMF etiology, correctly predicting inherited and likely immune BMF in 79% and 92% of cases, respectively. Our model represents a practical guide for BMF diagnosis and highlights the importance of clinical and laboratory variables in the initial evaluation, particularly telomere length. Our tool can be potentially used by general hematologists and health care providers not specialized in BMF, and in under-resourced centers, to prioritize patients for genetic testing or for expeditious treatment.
  • conferenceObject
    WHO-2016 Classification in ALL By Cytogenetics, FISH and Molecular Biology - Experience of Two Reference Centers in Brazil
    (2018) VELLOSO, Elvira D. R. P.; CORDEIRO, Maria Gabriella; LUCON, Danielle; KISHIMOTO, Renata; LEAL, Aline Medeiros; MAIA, Ana Carolina Arrais; BUCCHERI, Valeria; BENDIT, Israel; SILVA JR., Wellington Fernandes; MANGUEIRA, Cristovao; REGO, Eduardo Magalhaes; ROCHA, Vanderson
  • conferenceObject
    Retrospective Comparison between MEC and FLAG-Ida Regimens for Refractory or Relapsed Acute Myeloid Leukemia in Adults
    (2019) SILVA, Wellington F.; ROSA, Lidiane Ines Da; SEGURO, Fernanda S.; SILVEIRA, Douglas R. A.; NARDINELLI, Luciana; BUCCHERI, Valeria; VELLOSO, Elvira D. R. P.; ROCHA, Vanderson; REGO, Eduardo M.
  • article 15 Citação(ões) na Scopus
    Treating Adult Acute Lymphoblastic Leukemia in Brazil-Increased Early Mortality Using a German Multicenter Acute Lymphoblastic Leukemia-based regimen
    (2018) SILVA JUNIOR, Wellington Fernandes da; MEDINA, Andrezza Bertolaci; YAMAKAWA, Patricia Eiko; BUCCHERI, Valeria; VELLOSO, Elvira D. R. P.; ROCHA, Vanderson
    Studying adult acute lymphoblastic leukemia (ALL) in developing countries is essential, because few reports are available. We performed a retrospective medical record review of the adapted German Multicenter ALL regimen encompassing 59 patients treated in Brazil. A disappointing long-term survival rate of 15.3% was found, demonstrating that every regimen must be adjusted to a given population to avoid unacceptable toxicity. Background: Acute lymphoblastic leukemia (ALL) in adults is an invariably aggressive and rare disease. Its treatment is based on the use of multidrug regimens, which have been improved since the 1970s. Few published data are available on the results of adult ALL treatment in Latin America. Materials and Methods: We retrospectively analyzed the data from 59 patients with ALL treated from 2009 to 2015 at Hospital of Clinics of University of Sao Paulo, using an adapted German Multicenter ALL (GMALL) protocol (07/2003). Results: The median patient age was 35 years (range, 16-71 years), with 76% of new cases of B-cell lineage. Central nervous system involvement was present in 29%. Most patients were in the high-risk group, using the original GMALL criteria (68%). The early death rate was 17%, preventing early evaluation of the response in these patients. Despite a reasonable complete remission rate (76%), most patients eventually died of sepsis, especially during the induction phase and salvage regimens. The median overall survival was 17 months. Conclusion: Intensified chemotherapy protocols for adult ALL have succeeded in achieving better survival rates in adults, especially younger adults. The low overall survival found with GMALL in Brazil's public hospital denotes the importance of optimizing the adaptations of international protocols for treatment of ALL in nondeveloped countries and, in parallel, improving supportive care in public services.